Next Article in Journal
A New Self-Healing Degradable Copolymer Based on Polylactide and Poly(p-dioxanone)
Previous Article in Journal
Phytochemical Analysis and Evaluation of the Antioxidant, Antiproliferative, Antibacterial, and Antibiofilm Effects of Globularia alypum (L.) Leaves
Previous Article in Special Issue
Amine- and Amino Acid-Based Compounds as Carbonic Anhydrase Activators
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Molecules
Volume 28
Issue 10
10.3390/molecules28104020
molecules-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Inhibition Studies on Human and Mycobacterial Carbonic Anhydrases with N-((4-Sulfamoylphenyl)carbamothioyl) Amides

by
Morteza Abdoli
1,
Alessandro Bonardi
2,3,
Niccolò Paoletti
2,3,
Ashok Aspatwar
4,
Seppo Parkkila
4,5,
Paola Gratteri
3,
Claudiu T. Supuran
2,* and
Raivis Žalubovskis
1,6,*
1
Institute of Technology of Organic Chemistry, Faculty of Materials Science and Applied Chemistry, Riga Technical University, LV-1048 Riga, Latvia
2
Neurofarba Department, Universitàdegli Studi di Firenze, 50019 Florence, Italy
3
Laboratory of Molecular Modeling Cheminformatics & QSAR, Neurofarba Department, Università degli Studi di Firenze, 50019 Florence, Italy
4
Faculty of Medicine and Health Technology, Tampere University, 33520 Tampere, Finland
5
Fimlab Ltd., Tampere University Hospital, 33520 Tampere, Finland
6
Latvian Institute of Organic Synthesis, LV-1006 Riga, Latvia
*
Authors to whom correspondence should be addressed.
Molecules 2023, 28(10), 4020; https://doi.org/10.3390/molecules28104020
Submission received: 20 February 2023 / Revised: 25 April 2023 / Accepted: 9 May 2023 / Published: 11 May 2023
(This article belongs to the Special Issue Metalloenzyme Modulators and Enzyme Mimics: Synthesis and Applications)
Browse Figures
Review Reports Versions Notes

Abstract

:
A library of structurally diverse N-((4-sulfamoylphenyl)carbamothioyl) amides was synthesized by selective acylation of easily accessible 4-thioureidobenzenesulfonamide with various aliphatic, benzylic, vinylic and aromatic acyl chlorides under mild conditions. Inhibition of three α-class cytosolic human (h) carbonic anhydrases (CAs) (EC 4.2.1.1); that is, hCA I, hCA II and hCA VII and three bacterial β-CAs from Mycobacterium tuberculosis (MtCA1-MtCA3) with these sulfonamides was thereafter investigated in vitro and in silico. Many of the evaluated compounds displayed better inhibition against hCA I (KI = 13.3–87.6 nM), hCA II (KI = 5.3–384.3 nM), and hCA VII (KI = 1.1–13.5 nM) compared with acetazolamide (AAZ) as the control drug (KI values of 250, 12.5 and 2.5 nM, respectively, against hCA I, hCA II and hCA VII). The mycobacterial enzymes MtCA1 and MtCA2 were also effectively inhibited by these compounds. MtCA3 was, on the other hand, poorly inhibited by the sulfonamides reported here. The most sensitive mycobacterial enzyme to these inhibitors was MtCA2 in which 10 of the 12 evaluated compounds showed KIs (KI, the inhibitor constant) in the low nanomolar range.

1. Introduction

Carbonic anhydrases (CAs) (EC 4.2.1.1) constitute a superfamily of lyases, a class of enzymes that catalyze the interconversion between CO2 and water to bicarbonate and a proton [1], a simple but fundamental reaction that contributes to several important pathophysiological processes connected to pH buffering, metabolism, signaling and other processes [2]. According to their amino acid sequence similarity, eight genetically distinct families of CAs were described so far, including α, β, γ, δ, ζ, η, θ, and ι [3]. Human CAs (hCAs) belong to the α-class, which express 15 isoforms with different catalytic activity, tissue expression and subcellular localization [4]. Of these, twelve are catalytically active (CA I–IV, VA–VB, VI–VII, IX and XII–XIV), whereas three are inactive (CAs VIII, X and XI) [5]. It is well documented that abnormal expression and/or activities of CA isoforms are linked with various diseases, including glaucoma, epileptic seizures, obesity, cancer, neurological disorders, etc. [6]. Therefore, the isoform-selective inhibition of these isoforms is found in pharmacological applications in many areas.
Since the early 1940s when Mann and Keilin discovered that sulfonamides are potent inhibitors of CAs [7], a huge number of sulfonamide-based CAIs have been reported [8] and, as a result, many drugs containing a primary sulfonamide moiety are currently available on the market for the treatment of various diseases (Figure 1a) [9,10]. However, because hCA isoforms have a high degree of homology, clinical drugs designed to inhibit the enzymatic activity of a particular isoform can also bind to others with similar affinity, thus causing many undesirable side effects [11]. Therefore, many researchers around the world have been working to explore novel sulfonamide compounds with maximum inhibitory action against a particular isoform(s). In this context, over the last decade, several research groups have disclosed that sulfonamide–acyl thiourea derivatives were effective inhibitors of CAs (Figure 1b) [12,13,14,15,16]. In order to extend these efforts and in continuation of our interest in the study of sulfonamide CAIs [17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36], in the present study, we synthesized a panel of 12 structurally diverse N-((4-sulfamoylphenyl)carbamothioyl) amides by the reaction of easily available 4-thioureidobenzenesulfonamide with the appropriate acid chlorides and investigated their inhibitory activities against three human CAs (hCA I, hCA II and hCA VII) and three bacterial β-CAs from Mycobacterium tuberculosis (MtCA1-MtCA3), which were recently validated as effective targets for the development of antituberculosis agents [37,38,39,40,41,42,43], to discover possible promising drug candidate(s).

2. Results and Discussion

2.1. Chemistry

A series of N-((4-sulfamoylphenyl)carbamothioyl) amide derivatives were synthesized according to the general Scheme 1. All compounds were thoroughly characterized by HRMS, 1H NMR and 13C NMR which proved their structure (see Section 4 for details). 4-Thioureidobenzenesulfonamide 1 was synthesized according to previously reported procedures [17,18,19,20,21], and then it was subjected to acylation with various aliphatic, vinylic and aromatic acid chlorides of 2 to providethe desired compounds of 3 in satisfactory yields, ranging from 22% to 75%. Notably, the yields corresponded to the N-acylation step, not the overall yield.

2.2. Carbonic Anhydrase Inhibition

The N-((4-sulfamoylphenyl)carbamothioyl) amides 3a–l reported here were tested as inhibitors of three cytosolic hCA isoforms (hCA I, II and VII), as well as three bacterial β-CAs from M. tuberculosis (MtCA1-MtCA3) using a stopped-flow CO2 hydrase assay [44]. The classical sulfonamide CAI acetazolamide (5-acetamido-1,3,4-thiadiazole-2-sulfonamide (AAZ)) was used as the reference drug for the measurements reported in Table 1.
The analysis and interpretation of data presented in Table 1 led to the following structure–activity relationships (SARs):
(i)
The physiologically dominant cytosolic human isoform hCA I was effectively inhibited by all evaluated sulfonamides 3a–l, with KIs in the range of 13.3–87.6 nM. As shown in Table 1, all tested compounds exhibited better inhibition against this isozyme compared with acetazolamide (AAZ) as the control drug. Interestingly, the poorest inhibitor of the series, 3l, inhibited hCA I up to three-fold compared to the reference inhibitor (KI = 250 nM). Since the structure–activity relationship (SAR) was not flat, with the aim of simplifying its interpretation, the compounds were classified into five classes: (i) acyclic alkyl-; (ii) cyclic alkyl-; (iii) benzyl-; (iv) vinyl-; and (iv) aryl-substituted derivatives. The SARs for the linear alkyl-substituted compounds 3a–c and 3e–g indicated that a higher alkyl chain length leads to more potent inhibitory activities against hCA I. Therefore, hexanamide 3g exhibited the most engaging activity, with a KI value of 13.3 nM. Similarly, by the expansion of the ring size of the cyclic alkyl-substituted derivatives 3d,h, their inhibitory potency increased; albeit there is no clear relationship between the inhibitory activity of acyclic and cyclic series. On the other hand, the benzyl- and vinyl-substituted derivatives 3i and 3j,k, respectively, exhibited similar inhibitory activities, which were almost equal to the medium-sized ring alkane-substituted 3l. Finally, among the investigated compounds, the only aryl-substituted derivative, 3l, exhibited the poorest inhibition for this isozyme. In summary, the potency for the inhibition of hCA I by the newly designed compounds followed the order: long aliphatic chain (C6)-substituted > medium aliphatic chain (C2-C4)-substituted ≥ medium-sized cyclic aliphatic (C6)-substituted ≈ vinyl-substituted ≈ benzyl-substituted > small-sized cyclic aliphatic (C3)-substituted ≈ aryl-substituted derivatives.
(ii)
The physiologically most relevant and fastest isoform, hCA II, was also effectively inhibited by most of the evaluated sulfonamides, with KIs ranging between 5.3 and 384.3 nM. Notably, half of compounds reported here displayed better inhibitory activity towards hCA II compared to AAZ. Again, a linear alkyl-substituted sulfonamide, 3f, showed superior activity, with a KI value of 5.3 nM, which was 2.5-fold higher than that of AAZ. The SAR was rather similar to that outlined above for hCA I, with the most obvious difference being in the case of the aryl-substituted derivatives. While for hCA I the worst inhibition was observed for compound 3l, and this compound showed one of the best inhibition values of the series against hCA II (KI of 6.8 nM). Needless to say that the high similarity of the observed SARs for hCA I and hCA II can be explained by the high-sequence homology of the amino acid present within the active site of these isozymes [45].
(iii)
The other cytosolic isoform, hCA VII, which was recently validated as a therapeutic target in neuropathic pain [46], was also strongly inhibited by all evaluated compounds (KIs in the range of 1.1–13.5 nM) compared to AAZ with a KI of 2.5 nM. The data presented in Table 1 indicate that one-third of the compounds investigated here (3d–f and 3h) displayed even better inhibitory activities against hCA VII in comparison with AAZ. Among them, 3d showed superior selectivity against this isoform versus hCA I and hCA II, which was more than 46 and 202 times more selective against hCA VII vs. hCA I and hCA II, respectively. Therefore, this compound may be considered an interesting starting point for the development of hCA VII-selective inhibitors, which may be used as neuropathic-attenuating agents.
(iv)
As seen from the data in Table 1, the tested sulfonamides exhibited good to moderate inhibitory action against the mycobacterial enzyme MtCA1, with nanomolar to micromolar efficacies (KIs of 95.2 nM to 6.669 μM). The SAR is diverse from what was observed for the α-isoforms, except for the most massive aliphatic (C6)-substituted derivatives 3g,h, the rest of the studied derivatives were active in the nanomolar range. Compound 3d, which exhibited the weakest results for hCA I and II, displayed the best activity against MtCA1, with an KI value of 95.2 nM andfive-fold superior to acetazolamide (KI of 480 nM). The results are highly encouraging towards their future use in designing β-CA-selective inhibitors.
(v)
The second M. tuberculosis isoform, MtCA2, was the best inhibited bacterial CA among the three such enzymes investigated in this study, with N-((4-sulfamoylphenyl)carbamothioyl) amides 3a–l. Indeed, all of these compounds showed low nanomolar inhibition constants ranging between 3.4 and 57.1 nM. It is worthwhile to note that almost 85% of the tested compounds 3a–d and 3g–l displayed better inhibitory activities than AAZ. This means that all of the substitution patterns explored here led to highly effective MtCA2 inhibitors.
(vi)
MtCA3 was, on the other hand, less sensitive to inhibition with the evaluated compounds compared to MtCA1 and MtCA2, and the KIs were in the range of 446.6–9396 nM. In this case, the styrene-substituted derivative 3k demonstrated the best activity, with a KI value of 446.6 nM but was still 4.3-fold less potent than acetazolamide (KI of 104 nM).

3. In Silico Studies

In silico studies were performed to investigate indepth the binding properties of the best N-((4-sulfamoylphenyl)carbamothioyl) amides 3d and 3k towards the human α-CA I, II and VII and against the Mycobacterium tuberculosis isoforms MtCA1, MtCA2 and MtCA3, belonging to the β-class.
Because the 3D-solved structure of the MtCA3 isoform is not available to date, the homology model (HM) was developed using the solved coordinates of the “open” form of the β-CA from Synechocystis sp. PCC 6803 as a template (PDB 5SWC) [47]. The template shows the highest sequence identity percentage (34.1%) with the target (Figures S1–S4, Supplementary Materials). Docking was carried out using the best-scored model among the ones built by homology. It is noteworthy that, to the best of our knowledge, neither structural nor modeling studies have been reported to date on inhibitors of the MtCA3 isoform. All docking solutions obtained with the studied human CAs found the benzenesulfonamide bound to the zinc ion of the active site with the deprotonated nitrogen atom of the sulfonamide moiety (SO2NH−), completing the tetrahedral coordination sphere of the metal (Figure 2). Moreover, the benzenesulfonamide binding mode was stabilized by two H-bonds formed between the sulfonamide S=O and NH− groups with a backbone NH and side-chain OH of T199, respectively. The stabilization was further strengthened by van der Waals contacts (vdW) established by the aromatic ring with residues A121/V121 (CA I/CA II and CA VII), V143, L198 and W205.
In CA I, the C=O group of cyclopropane carboxamide pendant of 3d is an H-bond distance with the side-chain NH2 of Q92, a highly conserved residue of the hydrophilic half of the hCAs’ active site. Interestingly, the longer cinnamic tail of 3k is oriented towards the lipophilic part of the active site giving rise to vdW interactions with residues L131, A135, V207 and P202 and T-shaped π-π stacking contacts with the aromatic ring of the peculiar Y204 residue side chain (Figure 2A). This wide network of interactions could provide an explanation for the better CA I inhibitory activity of 3k than 3d.
In the active site of CA II, the C=S group of ligand 3d engages in an H-bond with the side-chain NH2 of Q92 and the cyclopropane ring lodges in the center of the active site, interacting with F131. The C=O group of the cinnamide pendant of 3k is H-bonded with the side-chain OH of T200. It is likely that the contribution to the stabilization of the docking pose given by the van der Waals contacts with P202, P201 and W5, coupled with the steric hindrance exerted by the proximity of the cinnamide pendant to the proton shuttle H64 residue, contributes to the better CA II KI value of 3k versus 3d (Figure 2B).
In CA VII, the C=O groups of both 3d and 3k engage in H-bonds with the side-chain NH2 of Q92 and Q67, respectively, placing the respective pendants towards K91, a peculiar residue of this isozyme. In particular, the cyclopropane ring of 3d interacts with F131 and the side-chain carbons of K91, while the aromatic ring of the longer cinnamic tail of 3k engages in π-cation interactions with the K91 side-chain NH3+. These interactions greatly influence the positioning of the pendant. However, the pose is also well destabilized by the proximity of the aromatic ring and the negatively charged sidechain of E69, which could explain the difference in the KI values observed for the derivatives 3k and 3d (Figure 2C).
All the β-CAs are characterized by a dimeric active site. Each of the M. tuberculosis CA isoforms (MtCA1, MtCA2 and MtCA3) has peculiar structural motifs that are between residues 91 and 109, 107 and 143, and 645 and 680 of MtCA1, MtCA2 and MtCA3-HM, respectively (Figure 3). The area of the enzymes resulting from the different random coil and α-helix patterns accommodates the tails of 3d and 3k. In all three enzyme isoforms, the pendants are stabilized by a series of van der Waals interactions, while the tetrahedral coordination sphere around the zinc ion is completed by the negatively charged nitrogen atom of the benzenesulfonamide moiety. In addition, an H-bond is established between the sulfonamide NH− and the side-chain COO- of D37/D53/D586 (MtCA1/MtCA2/MtCA3-HM), the residue of the highly conserved dyad Asp-Arg responsible for the form “open”/“closed” pH-dependent interconversion in the β-CAs. Other H-bonds involving the sulfonamide moiety are formed with G92 (MtCA1, N-H…NH2), Q42 (MtCA2, S=O…NH2), Q575(MtCA3-HM, S=O…NH2) Y603 (MtCA3-HM, S=O…H-O) and G609 (MtCA3-HM, S=O…H-N). The aromatic ring of benzenesulfonamide is stabilized by vdW interactions with A59, G92, M93, F96, M24, I73, L77 and L78 in MtCA1, with A75, G108, A109, A112 and Y89 in MtCA2 and with L608, A646, A647, A650, M663 A109 and F627 in MtCA3-HM. In the last two isoenzymes, π-π stacking with Y89 (MtCA2) and F627 (MtCA3-HM) is also present (Figure 3).
Of relevance in MtCA1 is the H-bond formation between the side-chain T95 OH and the amidic NH (calculated pKa = 8.01) of the cyclopropane carboxamide tail of 3d (Figure 3A). The calculated pKa of the amidic NH of ligand 3k is 6.67; the deprotonated form present at physiological pH = 7.2–7.4 is not able to engage an H-bond as a donor with T95, thus explaining the worst inhibition profile of 3k.
In MtCA2 active site, both ligands are stabilized by a wide network of hydrophobic interactions with A112, A115 (3k), T121(3k) and P123 (Figure 3B). The stronger benzenesulfonamide interaction within the MtCA2 active site joined with the hydrophobic nature of the ligand pendants and the target counterpart resulted in better KI values versus MtCA1.
Along with the prevalence of hydrophobic residues, the corresponding pocket of the homology-built model of MtCA3 also contains hydrophilic residues, which probably makes the interaction of 3d and 3k suboptimal with respect to the other MtCAs (Figure 3C). Indeed, the hydrophobic pendant of 3d is oriented towards the side-chain COO- of E653, while the aromatic ring of the cinnamic tail of 3k, achieving the complementary hydrophobic residues P656 and A657, is closed to the hydrophilic residues E653, T659 and T660.

4. Materials and Methods

4.1. Chemistry

Unlike 4-thioureidobenzenesulfonamide, which was prepared according to procedures in the literature, the other reagents, solvents and starting materials were obtained from commercial sources and were used as received without further purification. Thin-layer chromatography (TLC) was performed on silica gel, and spots were visualized with UV light (254 and 365 nm). The 1H and 13C NMR spectra were recorded with 500 and 125 MHz, respectively, using Bruker Avance instrument in DMSO-d6 with chemical shifts values (δ) in ppm relative to tetramethylsilane (TMS). High-resolution mass spectra (HRMS) were recorded on a mass spectrometer with a Q-TOF micro mass analyzer using the ESI technique.

4.2. Synthesis

4.2.1. Synthesis of N-((4-Sulfamoylphenyl)carbamothioyl)acetamide 3a

To a solution of 4-thioureidobenzenesulfonamide (1) (0.5 g, 2.16 mmol, 1.0 equiv.) and NaI (0.648 g, 4.32 mmol, 2.0 equiv.) in dry DMF (5 mL) at 0 °C, acetyl chloride (2a) (0.154 mL, 2.16 mmol, 1.0 equiv.) was slowly added while stirring. The reaction was allowed to warm to 20 °C and then stirred for 1 h. The reaction mixture was then treated with water (80 mL) and Et2O (10 mL), and the solution was vigorously stirred for 3 h. The solids formed in the organic phase were filtered and washed with water (30 mL) and Et2O (20 mL) to afford 3a in 28% yield (168 mg) as a white powder.
Molecules 28 04020 i001
1H NMR (500 MHz, DMSO-d6) δ = 2.20 (s, 3H), 7.42 (s, 2H), 7.45–7.91 (m, 4H), 11.63 (s, 1H), 12.67 (s, 1H) ppm 13C NMR (125 MHz, DMSO-d6) δ = 24.8, 125.2, 127.2, 141.6, 142.2, 173.8, 180.0 ppm HRMS (ESI) [M + H]+: m/z calcd. for (C9H12N3O3S2) 274.0320. Found: 274.0322.

4.2.2. Synthesis of N-((4-Sulfamoylphenyl)carbamothioyl)propionamide 3b

To a solution of 4-thioureidobenzenesulfonamide (1) (0.5 g, 2.16 mmol, 1.0 equiv.) and NaI (0.648 g, 4.32 mmol, 2.0 equiv.) in dry DMF (5 mL) at 0 °C, propionyl chloride (2b) (0.188 mL, 2.16 mmol, 1.0 equiv.) was slowly added with stirring. The reaction was allowed to warm to 20 °C and then stirred for 15 min. The reaction mixture was then treated with water (100 mL) and the solids formed were filtered and washed with water (30 mL) and DCM (20 mL) to afford 3b in a 51% yield (317 mg) as a white powder.
Molecules 28 04020 i002
1H NMR (500 MHz, DMSO-d6) δ = 0.96 (t, 3H, J = 6.8 Hz), 2.15 (q, 2H, J = 6.8 Hz), 7.51 (s, 2H), 7.54 (d, 2H, J = 7.8 Hz), 7.89 (d, 2H, J = 7.8 Hz), 9.88 (s, 1H), 10.27 (s, 1H) ppm 13C NMR (125 MHz, DMSO-d6) δ = 9.7, 32.3, 127.2, 131.3, 144.5, 145.0, 176.6, 185.9 ppm HRMS (ESI) [M + H]+: m/z calcd. for (C10H14N3O3S2) 288.0477. Found: 288.0478.

4.2.3. Synthesis of N-((4-Sulfamoylphenyl)carbamothioyl)butyramide 3c

To a solution of 4-thioureidobenzenesulfonamide (1) (0.5 g, 2.16 mmol, 1.0 equiv.) and NaI (0.648 g, 4.32 mmol, 2.0 equiv.) in dry DMF (5 mL) at 0 °C butyryl chloride (2c) (0.223 mL, 2.16 mmol, 1.0 equiv.) was slowly added with stirring. The reaction was allowed to warm to 20 °C and then stirred for 12 h. The reaction mixture was then treated with water (100 mL) and the solids formed were filtered and washed with water (30 mL) and DCM (20 mL) to afford 3c in 34% yield (220 mg) as a light yellow powder.
Molecules 28 04020 i003
1H NMR (500 MHz, DMSO-d6) δ = 0.95 (t, 3H, J = 7.0 Hz), 1.59–1.67 (m, 2H), 1.63 (t, 2H, J = 6.8 Hz), 7.41 (s, 2H), 7.86 (d, 2H, J = 8.1 Hz), 7.90 (d, 2H, J = 8.1 Hz), 11.59 (s, 1H), 12.72 (s, 1H) ppm 13C NMR (125 MHz, DMSO-d6) δ = 14.4, 18.7, 38.6, 125.2, 127.2, 141.6, 142.2, 176.4, 180.0 ppm HRMS (ESI) [M + H]+: m/z calcd. for (C11H16N3O3S2) 302.0633. Found: 302.0640.

4.2.4. Synthesis of N-((4-Sulfamoylphenyl)carbamothioyl)cyclopropanecarboxamide 3d

To a solution of 4-thioureidobenzenesulfonamide (1) (0.5 g, 2.16 mmol, 1.0 equiv.) and NaI (0.648 g, 4.32 mmol, 2.0 equiv.) in dry DMF (5 mL) at 0 °C cyclopropanecarbonyl chloride (2d) (0.196 mL, 2.16 mmol, 1.0 equiv.) was slowly added with stirring. The reaction was allowed to warm to 20 °C and stirred for 15 min. The reaction mixture was then treated with water (100 mL) and the solids formed were filtered and washed with water (30 mL) and DCM (20 mL) to afford 3d in 75% yield (489 mg) as a white powder.
Molecules 28 04020 i004
1H NMR (500 MHz, DMSO-d6) δ = 0.82–0.86 (m, 2H), 0.97–1.02 (m, 2H), 1.28–1.34 (m, 1H), 7.51 (s, 2H), 7.58 (d, 2H, J = 8.2 Hz), 7.91 (d, 2H, J = 8.2 Hz), 9.91 (s, 1H), 10.14 (s, 1H) ppm 13C NMR (125 MHz, DMSO-d6) δ = 11.5, 17.0, 127.4, 131.1, 144.4, 145.1, 175.9, 185.8 ppm HRMS (ESI) [M + H]+: m/z calcd. for (C11H14N3O3S2) 300.0477. Found: 300.0480.

4.2.5. Synthesis of N-((4-sulfamoylphenyl)carbamothioyl)isobutyramide 3e

To a solution of 4-thioureidobenzenesulfonamide (1) (0.5 g, 2.16 mmol, 1.0 equiv.) and NaI (0.648 g, 4.32 mmol, 2.0 equiv.) in dry DMF (5 mL) at 0 °C, isobutyryl chloride (2e) (0.226 mL, 2.16 mmol, 1.0 equiv.) was slowly added with stirring. The reaction was allowed to warm to 20 °C and then stirred for 1 h. The reaction mixture was then treated with water (100 mL) and the solids formed were filtered and washed with water (30 mL) and DCM (20 mL) to afford 3e in 72% yield (469 mg) as a white powder.
Molecules 28 04020 i005
1H NMR (500 MHz, DMSO-d6) δ = 1.48 (d, 6H, J = 6.2 Hz), 2.82–2.88 (m, 1H), 7.41 (s, 2H), 7.86 (d, 2H, J = 7.9 Hz), 7.90 (d, 2H, J = 7.9 Hz), 11.60 (s, 1H), 12.79 (s, 1H) ppm 13C NMR (125 MHz, DMSO-d6) δ = 19.8, 35.4, 125.2, 127.2, 141.6, 142.2, 180.3, 180.3 ppm HRMS (ESI) [M + H]+: m/z calcd.For (C11H16N3O3S2) 302.0633. Found: 302.0645.

4.2.6. Synthesis of 3-methyl-N-((4-sulfamoylphenyl)carbamothioyl)butanamide 3f

To a solution of 4-thioureidobenzenesulfonamide (1) (0.5 g, 2.16 mmol, 1.0 equiv.) and NaI (0.648 g, 4.32 mmol, 2.0 equiv.) in dry DMF (5 mL) at 0 °C, 3-methylbutanoyl chloride (2f) (0.264 mL, 2.16 mmol, 1.0 equiv.) was slowly added with stirring. The reaction was allowed to warm to 20 °C and then stirred for 2 h. The reaction mixture was then treated with water (100 mL) and the solids formed were filtered and washed with water (30 mL) and DCM (20 mL) to afford 3f in 31% yield (210 mg) as a white powder.
Molecules 28 04020 i006
1H NMR (500 MHz, DMSO-d6) δ = 0.93 (d, 6H, J = 6.6 Hz), 2.01–2.10 (m, 1H), 2.36 (d, 2H, J = 7.0 Hz), 7.39 (s, 2H), 7.82 (d, 2H, J = 8.7 Hz), 7.86 (d, 2H, J = 8.7 Hz), 11.57 (s, 1H), 12.69 (s, 1H) ppm 13C NMR (125 MHz, DMSO-d6) δ = 23.2, 25.7, 46.9, 127.3, 131.1, 144.4, 145.0, 174.8, 186.2 ppm HRMS (ESI) [M + H]+: m/z calcd. for (C12H18N3O3S2) 316.0790. Found: 316.0795.

4.2.7. Synthesis of N-((4-sulfamoylphenyl)carbamothioyl)hexanamide 3g

To a solution of 4-thioureidobenzenesulfonamide (1) (0.5 g, 2.16 mmol, 1.0 equiv.) and NaI (0.648 g, 4.32 mmol, 2.0 equiv.) in dry DMF (5 mL) at 0 °C, hexanoyl chloride (2g) (0.302 mL, 2.16 mmol, 1.0 equiv.) was slowly added with stirring. The reaction was allowed to warm to 20 °C and then stirred for 12 h. The reaction mixture was then treated with water (80 mL) and Et2O (10 mL) and the solution was vigorously stirred. The solids formed in the organic phase were filtered and washed with water (30 mL) and Et2O (20 mL), and DCM (20 mL) to afford 3g in 35% yield (258 mg) as a light yellow powder.
Molecules 28 04020 i007
1H NMR (500 MHz, DMSO-d6) δ = 0.91 (t, 3H, J = 6.9 Hz), 1.28–1.36 (m, 4H), 1.57–1.65 (m, 2H), 2.50 (t, 2H, J = 6.5 Hz), 7.41 (s, 2H), 7.86 (d, 2H, J = 7.4 Hz), 7.90 (d, 2H, J = 7.4 Hz), 11.59 (s, 1H), 12.72 (s, 1H) ppm 13C NMR (125 MHz, DMSO-d6) δ = 14.7, 22.8, 24.9, 31.6, 36.7, 125.1, 127.2, 141.6, 142.2, 176.6, 180.0 ppm HRMS (ESI) [M + H]+: m/z calcd. for (C13H20N3O3S2) 330.0946. Found: 330.0952.

4.2.8. Synthesis of N-((4-Sulfamoylphenyl)carbamothioyl)cyclohexanecarboxamide 3h

To a solution of 4-thioureidobenzenesulfonamide (1) (0.5 g, 2.16 mmol, 1.0 equiv.) and NaI (0.648 g, 4.32 mmol, 2.0 equiv.) in dry DMF (5 mL) at 0 °C, cyclohexanecarbonyl chloride (2h) (0.291 mL, 2.16 mmol, 1.0 equiv.) was slowly added with stirring. The reaction was allowed to warm to 20 °C and then stirred for 4 h. The reaction mixture was then treated with water (80 mL) and Et2O (10 mL), and the solution was vigorously stirred. The solids formed in the organic phase were filtered and washed with water (30 mL) and Et2O (20 mL), and DCM (20 mL) to afford 3h in 29% yield (212 mg) as a white powder.
Molecules 28 04020 i008
1H NMR (500 MHz, DMSO-d6) δ = 1.19–1.31 (m, 3H), 1.35–1.43 (m, 2H), 1.64–1.70 (m, 1H), 1.75–1.90 (m, 4H), 2.58–2.64 (m, 1H), 7.41 (s, 2H), 7.86 (d, 2H, J = 7.9 Hz), 7.90 (d, 2H, J = 7.9 Hz), 11.54 (s, 1H), 12.73 (s, 1H) ppm 13C NMR (125 MHz, DMSO-d6) δ = 25.9, 26.1, 29.5, 44.8, 125.1, 127.2, 141.6, 142.2, 179.3, 180.3 ppm HRMS (ESI) [M + H]+: m/z calcd. for (C14H20N3O3S2) 342.0946. Found: 342.0950.

4.2.9. Synthesis of 2-(Naphthalen-1-yl)-N-((4-sulfamoylphenyl)carbamothioyl)acetamide 3i

To a solution of 4-thioureidobenzenesulfonamide (1) (0.5 g, 2.16 mmol, 1.0 equiv.) and NaI (0.648 g, 4.32 mmol, 2.0 equiv.) in dry DMF (5 mL) at 0 °C, 2-(naphthalen-1-yl)acetyl chloride (2i) (0.443 mL, 2.16 mmol, 1.0 equiv.) was slowly added with stirring. The reaction was allowed to warm to 20 °C and then stirred for 12 h. The reaction mixture was then treated with water (80 mL) and Et2O (10 mL), and the solution was vigorously stirred. The solids formed in the organic phase were filtered and washed with water (30 mL) and tBuOMe (20 mL), and MeOH (20 mL) to afford 3i in 22% yield (189 mg) as a white powder.
Molecules 28 04020 i009
1H NMR (500 MHz, DMSO-d6) δ = 4.02 (s, 2H), 7.37–7.60 (m, 6H), 7.79–7.97 (m, 7H), 10.04 (s, 1H), 10.19 (s, 1H) ppm 13C NMR (125 MHz, DMSO-d6) δ = 42.7, 125.0, 126.3, 126.6, 127.3, 127.5, 128.6, 129.4, 131.1, 131.7, 132.8, 134.2, 144.7, 145.0, 173.4, 186.2 ppm HRMS (ESI) [M + H]+: m/z calcd. for (C19H18N3O3S2) 400.0790. Found: 400.0805.

4.2.10. Synthesis of N-((4-Sulfamoylphenyl)carbamothioyl)but-2-enamide 3j

To a solution of 4-thioureidobenzenesulfonamide (1) (0.5 g, 2.16 mmol, 1.0 equiv.) in dry DMF (5 mL) at 0 °C but-2-enoyl chloride (2j) (0.277 mL, 2.16 mmol, 1.0 equiv.) was slowly added with stirring. The reaction was allowed to warm to 20 °C and then stirred for 2 h. The reaction mixture was then treated with water (100 mL), and the solids formed were filtered and washed with water (30 mL) and iPrOH (20 mL) to afford 3j in 46% yield (299 mg) as an orange powder.
Molecules 28 04020 i010
1H NMR (500 MHz, DMSO-d6) δ = 1.94 (d, 3H, J = 5.7 Hz), 6.38 (d, 1H, J = 15.3 Hz), 7.05–7.13 (m, 1H), 7.42 (s, 2H), 7.87 (d, 2H, J = 8.0 Hz), 7.92 (d, 2H, J = 8.0 Hz), 11.62 (s, 1H), 12.88 (s, 1H) ppm 13C NMR (125 MHz, DMSO-d6) δ = 19.1, 124.7, 125.1, 127.2, 141.6, 142.2, 147.3, 167.0, 180.3 ppm HRMS (ESI) [M + H]+: m/z calcd. for (C11H14N3O3S2) 300.0477. Found: 300.0488.

4.2.11. Synthesis of N-((4-Sulfamoylphenyl)carbamothioyl)cinnamamide 3k

To a solution of 4-thioureidobenzenesulfonamide (1) (0.5 g, 2.16 mmol, 1.0 equiv.) in dry DMF (5 mL) at 0 °C cinnamoyl chloride (2k) (0.329 mL, 2.16 mmol, 1.0 equiv.) was slowly added with stirring. The reaction was allowed to warm to 20 °C and then stirred for 1 h. The reaction mixture was then treated with water (100 mL), and the solids formed were filtered and washed with water (30 mL) and DCM (20 mL) to afford 3k in 31% yield (244 mg) as a light yellow powder.
Molecules 28 04020 i011
1H NMR (500 MHz, DMSO-d6) δ = 6.45 (d, 1H, J = 15.4 Hz), 7.44–7.55 (m, 9H), 7.70 (d, 1H, J = 15.4 Hz), 7.93 (d, 2H, J = 6.5 Hz), 10.03 (s, 2H) ppm 13C NMR (125 MHz, DMSO-d6) δ = 120.8, 127.5, 129.1, 130.0, 130.6, 131.6, 135.0, 144.3, 144.5, 144.6, 167.4, 186.3 ppm HRMS (ESI) [M + H]+: m/z calcd. for (C16H16N3O3S2) 362.0633. Found: 362.0636.

4.2.12. Synthesis of 4-nitro-N-((4-sulfamoylphenyl)carbamothioyl)benzamide 3l

To a solution of 4-thioureidobenzenesulfonamide (1) (0.5 g, 2.16 mmol, 1.0 equiv.) in dry DMF (5 mL) at 0 °C 4-nitrobenzoyl chloride (2l) (0.401 g, 2.16 mmol, 1.0 equiv.) was slowly added with stirring. The reaction was allowed to warm to 20 °C and then stirred for 1 h. The reaction mixture was then treated with water (100 mL), and the solids formed were filtered and washed with water (30 mL) and Et2O (20 mL) to afford 3l in 32% yield (267 mg) as a white powder.
Molecules 28 04020 i012
1H NMR (500 MHz, DMSO-d6) δ = 7.47 (s, 2H), 7.52 (d, 2H, J = 7.9 Hz), 7.85 (d, 2H, J = 7.9 Hz), 7.89 (d, 2H, J = 8.1 Hz), 8.30 (d, 2H, J = 8.1 Hz), 9.66 (s, 1H), 10.06 (s, 1H) ppm 13C NMR (125 MHz, DMSO-d6) δ = 124.4, 127.5, 129.6, 130.2, 142.4, 143.8, 144.8, 149.5, 169.5, 187.1 ppm HRMS (ESI) [M + H]+: m/z calcd.For (C14H13N4O5S2) 381.0327. Found: 381.0330.

4.3. CA Inhibitory Assay

An applied photophysics stopped-flow instrument was used for assaying the CA catalyzed CO2 hydration activity [44]. Phenol red (at a concentration of 0.2 mM) was used as an indicator, working at an absorbance maximum of 557 nm, with 20 mM Hepes (pH 7.5) as buffer for α-CAs or 20 mM TRIS (pH 8.4) as a buffer for β-CAs and 20 mM Na2SO4 (for maintaining constant the ionic strength), following the initial rates of the CA-catalyzed CO2 hydration reaction for a period of 10–100 s. The CO2 concentrations ranged from 1.7 to 17 mM for the determination of the kinetic parameters and inhibition constants. For each inhibitor, at least six traces of the initial 5–10% of the reaction were used for determining the initial velocity. The unanalyzed rates were determined in the same manner and subtracted from the total observed rates. Stock solutions of inhibitor (0.1 mM) were prepared in distilled–deionized water and dilutions up to 0.01 nM were conducted thereafter with the assay buffer. Inhibitor and enzyme solutions were preincubated together for 6 h at room temperature prior to assay in order to allow for the formation of the E–I complex. The inhibition constants were obtained by nonlinear least squares methods using PRISM 3 and the Cheng–Prusoff equation, as reported earlier [48,49,50,51,52], and represent the mean from at least three different determinations. All CA isoforms were recombinant ones obtained in-house as reported earlier [53,54,55,56,57,58], and their concentrations in the assay system ranged between 7.6 and 12.5 nM.

4.4. In Silico Studies

The primary sequence of MtCA3 was retrieved from the UniProt Consortium. The crystal structure of β-CA from Synechocystis sp. PCC 6803 (PDB 5SWC; resolution 1.45 Å) [47] was used as a template in the homology modeling procedure (sequence alignment is reported in Figure S1, Supplementary Materials). Multiple models were generated using the Prime module of Schrödinger [59] and the SwissModel platform (https://swissmodel.expasy.org/ (accessed on 29 March 2023)) [60] and submitted to loop refinements and quality evaluation procedures (Figures S2 and S3, Table S1, Supplementary Materials). The best-scored structure of MtCA3 and the crystal structure of CA I (PDB 2NMX) [61], CA II (PDB 3K34) [62], CA VII (PDB 6H38) [63], MtCA1 (PDB 1YLK) [43] and MtCA2 (PDB 2A5V) [42] downloaded by Protein Data Bank (RCSB.org) [64] were prepared using the Protein Preparation module implemented in Maestro Schrödinger suite [59,65,66,67,68,69], assigning bond orders, adding hydrogens, deleting water molecules and optimizing H-bonding networks. Finally, energy minimization with a root mean square deviation (RMSD) value of 0.30 was applied using an optimized potential for liquid simulation (OPLS4) force field [70,71,72,73,74]. The 3D ligand structures were prepared using Maestro [65] and evaluated for their ionization states at pH 7.3 ± 1.0 with Epik [66]. The conjugate gradient method in Macromodel [67] was used for energy minimization (maximum iteration number: 2500; convergence criterion: 0.05 Kcal/mol/Å2). The grids for docking were centered in the centroid of the complexed ligand. The docking studies were carried out with the program Glide [68] using the standard precision (SP) mode. 3D ligand structures were prepared using Maestro [65]. Figures were generated with Maestro and Chimera [59,65,66,67,68,69,75].

5. Conclusions

A panel of 12 structurally diverse N-((4-sulfamoylphenyl)carbamothioyl) amides were synthesized using selective acylation of easily available 4-thioureidobenzenesulfonamide with various aliphatic, benzylic, vinylic and aromatic acyl chlorides under mild conditions. The compounds were investigated as inhibitors of three human carbonic anhydrases (hCA I, hCA II and hCA VII) and three bacterial β-CAs from Mycobacterium tuberculosis (MtCA1-MtCA3). The results indicated that all targeted compounds had a higher inhibitory activity against hCA I than the standard drug, AAZ. On the other hand, 6 and 5 of the 12 evaluated compounds exhibited better or similar inhibition against hCA II and hCA VII, respectively, compared with AAZ. Of all the compounds investigated, 3d exhibited superior selectivity against the brain-associated hCA VII isoform versus hCA I and hCA II, which was more than 46 and 202 times, respectively, more selective. Therefore, this compound may be considered an interesting starting point for the development of hCA VII-selective inhibitors which may be used as neuropathic-attenuating agents. In association with inhibition of bacterial β-CAs, the results showed that the assayed compounds were preferential inhibitors of MtCA2. Specially, compound 3g displayed superior inhibitory activity with KI values of 3.4 nM (three-fold higher than that of AAZ) and showed considerably effective selectivity of MtCA1/MtCA2 (>1033) and MtCA3/MtCA2 (>211). Therefore, this compound could be a potential and promising candidate for further investigations and in vivo experimentations for antibacterial drug discovery. Moreover, the binding mode of compounds 3d and 3k was investigated in silico in the active site of the six studied CA isoforms to unveil the relationship between the structural features and inhibition profiles. The absence of a 3D-solved structure of the MtCA3 β-CA required its homology model building, resulting in the first work that report structural information on this β-CA.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/molecules28104020/s1.

Author Contributions

Methodology, S.P.; Formal analysis, P.G.; Investigation, M.A., A.B., N.P., A.A. and P.G.; Supervision, C.T.S. and R.Ž. All authors have read and agreed to the published version of the manuscript.

Funding

This work was supported by the European Regional Development Fund (ERDF) (Project No:1.1.1.2/VIAA/3/19/398). We are grateful to the Finnish Cultural Foundation (AA), Tampere Tuberculosis Foundation (AA), Jane & Aatos Erkko Foundation (SP) and Finnish Foundation for Cardiovascular Research and the Academy of Finland (SP).

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

The authors confirm that the data supporting the findings of this study are available within the article and its Supplementary Materials.

Conflicts of Interest

The authors declare no conflict of interest.

Sample Availability

Not applicable.

References

  1. Supuran, C.T. Structure and function of carbonic anhydrases. Biochem. J. 2016, 473, 2023–2032. [Google Scholar] [CrossRef] [PubMed]
  2. Supuran, C.T.; Scozzafava, A. Carbonic anhydrases as targets for medicinal chemistry. Bioorg. Med. Chem. 2007, 15, 4336–4350. [Google Scholar] [CrossRef] [PubMed]
  3. Nocentini, A.; Supuran, C.T.; Capasso, C. An overview on the recently discovered iota-carbonic anhydrases. J. Enzyme Inhib. Med. Chem. 2021, 36, 1988–1995. [Google Scholar] [CrossRef] [PubMed]
  4. Aspatwar, A.; Tolvanen, M.E.E.; Barker, H.; Syrjänen, L.; Valanne, S.; Purmonen, S.; Waheed, A.; Sly, W.S.; Parkkila, S. Carbonic anhydrases in metazoan model organisms: Molecules, mechanisms, and physiology. Physiol. Rev. 2022, 102, 1327–1383. [Google Scholar] [CrossRef] [PubMed]
  5. Supuran, C.T. Carbonic anhydrases—An overview. Curr. Pharm. Des. 2008, 14, 603–614. [Google Scholar] [CrossRef] [PubMed]
  6. Alterio, V.; Kellner, M.; Esposito, D.; Liesche-Starnecker, F.; Bua, S.; Supuran, C.T.; Monti, S.M.; Zeidler, R.; De Simone, G. Biochemical and structural insights into carbonic anhydrase XII/Fab6A10 complex. J. Mol. Biol. 2019, 431, 4910–4921. [Google Scholar] [CrossRef]
  7. Mann, T.; Keilin, D. Sulphanilamide as a specific inhibitor of carbonic anhydrase. Nature 1940, 146, 164–165. [Google Scholar] [CrossRef]
  8. Supuran, C.T.; Scozzafava, A.; Casini, A. Carbonic anhydrase inhibitors. Med. Res. Rev. 2003, 23, 146–189. [Google Scholar] [CrossRef]
  9. Supuran, C.T. Carbonic anhydrases: Novel therapeutic applications for inhibitors and activators. Nat. Rev. Drug Discov. 2008, 7, 168–181. [Google Scholar] [CrossRef]
  10. Scott, K.A.; Njardarson, J.T. Analysis of US FDA-Approved Drugs Containing Sulfur Atoms. Top. Curr. Chem. 2018, 376, 5. [Google Scholar] [CrossRef]
  11. Supuran, C.T. Emerging role of carbonic anhydrase inhibitors. Clin. Sci. 2021, 135, 1233–1249. [Google Scholar] [CrossRef] [PubMed]
  12. Zaib, S.; Saeed, A.; Stolte, K.; Flörke, U.; Shahid, M.; Iqbal, J. New aminobenzenesulfonamide-thiourea conjugates: Synthesis and carbonic anhydrase inhibition and docking studies. Eur. J. Med. Chem. 2014, 78, 140–150. [Google Scholar] [CrossRef]
  13. Saeed, A.; Al-Rashida, M.; Hamayoun, M.; Mumtaz, A.; Iqbal, J. Carbonic anhydrase inhibition by 1-aroyl-3-(4-aminosulfonylphenyl)thioureas. J. Enzyme Inhib. Med. Chem. 2014, 29, 901–905. [Google Scholar] [CrossRef] [PubMed]
  14. Tugrak, M.; Gul, H.I.; Demir, Y.; Gulcin, I. Synthesis of benzamide derivatives with thiourea-substituted benzenesulfonamides as carbonic anhydrase inhibitors. Arch. Pharm. 2021, 354, 2000230. [Google Scholar] [CrossRef] [PubMed]
  15. Mahmood, S.U.; Saeed, A.; Bua, S.; Nocentini, A.; Gratteri, P.; Supuran, C.T. Synthesis, biological evaluation and computational studies of novel iminothiazolidinone benzenesulfonamides as potent carbonic anhydrase II and IX inhibitors. Bioorg. Chem. 2018, 77, 381–386. [Google Scholar] [CrossRef]
  16. Fattah, T.A.; Bua, S.; Saeed, A.; Shabir, G.; Supuran, C.T. 3-Aminobenzenesulfonamides incorporating acylthiourea moieties selectively inhibit the tumor-associated carbonic anhydrase isoform IX over the off-target isoforms I, II and IV. Bioorg. Chem. 2019, 82, 123–128. [Google Scholar] [CrossRef]
  17. Abdoli, M.; Angeli, A.; Bozdag, M.; Carta, F.; Kakanejadifard, A.; Saeidian, H.; Supuran, C.T. Synthesis and carbonic anhydrase I, II, VII, and IX inhibition studies with a series of benzo[d]thiazole-5- and 6-sulfonamides. J. Enzyme Inhib. Med. Chem. 2017, 32, 1071–1078. [Google Scholar] [CrossRef]
  18. Abdoli, M.; Bozdag, M.; Angeli, A.; Supuran, C.T. Benzamide-4-Sulfonamides Are Effective Human Carbonic Anhydrase I, II, VII, and IX Inhibitors. Metabolites 2018, 8, 37. [Google Scholar] [CrossRef]
  19. Abdoli, M.; Giovannuzzi, S.; Supuran, C.T.; Žalubovskis, R. 4-(3-Alkyl/benzyl-guanidino)benzenesulfonamides as selective carbonic anhydrase VII inhibitors. J. Enzyme Inhib. Med. Chem. 2022, 37, 1568–1576. [Google Scholar] [CrossRef]
  20. Abdoli, M.; Bonardi, A.; Supuran, C.T.; Žalubovskis, R. 4-Cyanamidobenzenesulfonamide derivatives: A novel class of human and bacterial carbonic anhydrase inhibitors. J. Enzyme Inhib. Med. Chem. 2023, 38, 156–165. [Google Scholar] [CrossRef]
  21. Abdoli, M.; De Luca, V.; Capasso, C.; Supuran, C.T.; Žalubovskis, R. Benzenesulfonamides Incorporating Hydantoin Moieties Effectively Inhibit Eukaryoticand Human Carbonic Anhydrases. Int. J. Mol. Sci. 2022, 23, 14115. [Google Scholar] [CrossRef] [PubMed]
  22. Ivanova, J.; Abdoli, M.; Nocentini, A.; Žalubovskis, R.; Supuran, C.T. 1,2,3-Benzoxathiazine-2,2-dioxides—Effective inhibitors of human carbonic anhydrases. J. Enzyme Inhib. Med. Chem. 2023, 38, 225–238. [Google Scholar] [CrossRef] [PubMed]
  23. Abdoli, M.; De Luca, V.; Capasso, C.; Supuran, C.T.; Žalubovskis, R. Inhibition studies on carbonic anhydrase isoforms I, II, IX and XII with a series of sulfaguanidines. ChemMedChem. 2023, 18, e202200658. [Google Scholar] [CrossRef]
  24. Abdoli, M.; De Luca, V.; Capasso, C.; Supuran, C.T.; Žalubovskis, R. Novel thiazolone-benzenesulphonamide inhibitors of human and bacterial carbonic anhydrases. J. Enzyme Inhib. Med. Chem. 2023, 38, 2163243. [Google Scholar] [CrossRef]
  25. Abdoli, M.; Bonardi, A.; Supuran, C.T.; Žalubovskis, R. Investigation of novel alkyl/benzyl (4-sulphamoylphenyl)carbamimidothioates as carbonic anhydrase inhibitors. J. Enzyme Inhib. Med. Chem. 2023, 38, 2152811. [Google Scholar] [CrossRef] [PubMed]
  26. Ivanova, J.; Abdoli, M.; Nocentini, A.; Žalubovskis, R.; Supuran, C.T. Derivatives of 4-methyl-1,2,3-benzoxathiazine 2,2-dioxide as selective inhibitors of human carbonic anhydrases IX and XII over the cytosolic isoforms I and II. J. Enzyme Inhib. Med. Chem. 2023, 38, 2170370. [Google Scholar] [CrossRef] [PubMed]
  27. Abdoli, M.; Supuran, C.T.; Žalubovskis, R. 2-((1H-Benzo [d] imidazol-2-yl) amino) benzo [d] thiazole-6-sulphonamides: A class of carbonic anhydrase II and VII-selective inhibitors. J. Enzyme Inhib. Med. Chem. 2023, 38, 2174981. [Google Scholar] [CrossRef]
  28. Alterio, V.; Tanc, M.; Ivanova, J.; Zalubovskis, R.; Vozny, I.; Monti, S.M.; Di Fiore, A.; De Simone, G.; Supuran, C.T. X-ray crystallographic and kinetic investigations of 6-sulfamoyl-saccharin as a carbonic anhydrase inhibitor. Org. Biomol. Chem. 2015, 13, 4064–4069. [Google Scholar] [CrossRef]
  29. Grandane, A.; Nocentini, A.; Werner, T.; Zalubovskis, R.; Supuran, C.T. Benzoxepinones: A new isoform-selective class of tumor associated carbonic anhydrase inhibitors. Bioorg. Med. Chem. 2020, 28, 115496. [Google Scholar] [CrossRef]
  30. Grandāne, A.; Nocentini, A.; Domračeva, I.; Žalubovskis, R.; Supuran, C.T. Development of oxathiino[6,5-b]pyridine 2,2-dioxide derivatives as selective inhibitors of tumor-related carbonic anhydrases IX and XII. Eur. J. Med. Chem. 2020, 200, 112300. [Google Scholar] [CrossRef]
  31. Krasavin, M.; Sharonova, T.; Sharoyko, V.; Zhukovsky, D.; Kalinin, S.; Žalubovskis, R.; Tennikova, T.; Supuran, C.T. Combining carbonic anhydrase and thioredoxin reductase inhibitory motifs within a single molecule dramatically increases its cytotoxicity. J. Enzyme Inhib. Med. Chem. 2020, 35, 665–671. [Google Scholar] [CrossRef] [PubMed]
  32. Podolski-Renić, A.; Dinić, J.; Stanković, T.; Jovanović, M.; Ramović, A.; Pustenko, A.; Žalubovskis, R.; Pešić, M. Sulfocoumarins, specific carbonic anhydrase IX and XII inhibitors, interact with cancer multidrug resistant phenotype through pH regulation and reverse P-glycoprotein mediated resistance. Eur. J. Pharm. Sci. 2019, 138, 105012. [Google Scholar] [CrossRef]
  33. Ivanova, J.; Balode, A.; Žalubovskis, R.; Leitans, J.; Kazaks, A.; Vullo, D.; Tars, K.; Supuran, C.T. 5-Substituted-benzylsulfanyl-thiophene-2-sulfonamides with effective carbonic anhydrase inhibitory activity: Solution and crystallographic investigations. Bioorg. Med. Chem. 2017, 25, 857–863. [Google Scholar] [CrossRef] [PubMed]
  34. Pustenko, A.; Nocentini, A.; Balašova, A.; Alafeefy, A.; Krasavin, M.; Žalubovskis, R.; Supuran, C.T. Aryl derivatives of 3H-1,2-benzoxathiepine 2,2-dioxide as carbonic anhydrase inhibitors. J. Enzyme Inhib. Med. Chem. 2020, 35, 245–254. [Google Scholar] [CrossRef]
  35. Žalubovskis, R. In a search for selective inhibitors of carbonic anhydrases: Coumarin and its bioisosteres-synthesis and derivatization. Chem. Heterocycl. Comp. 2015, 51, 607–612. [Google Scholar] [CrossRef]
  36. Pustenko, A.; Nocentini, A.; Balašova, A.; Krasavin, M.; Žalubovskis, R.; Supuran, C.T. 7-Acylamino-3H-1,2-benzoxathiepine 2,2-dioxides as new isoform-selective carbonic anhydrase IX and XII inhibitors. J. Enzyme Inhib. Med. Chem. 2020, 35, 650–656. [Google Scholar] [CrossRef]
  37. Aspatwar, A.; Kairys, V.; Rala, S.; Parikka, M.; Bozdag, M.; Carta, F.; Supuran, C.T.; Parkkila, S. Mycobacterium tuberculosis β-carbonic anhydrases: Novel targets for developing antituberculosis drugs. Int. J. Mol. Sci. 2019, 20, 5153. [Google Scholar] [CrossRef]
  38. Wani, T.V.; Bua, S.; Khude, P.S.; Chowdhary, A.H.; Supuran, C.T.; Toraskar, M.P. Evaluation of sulphonamide derivatives acting as inhibitors of human carbonic anhydrase isoforms I, II and Mycobacterium tuberculosis β-class enzyme Rv3273. J. Enzyme Inhib. Med. Chem. 2018, 33, 962–971. [Google Scholar] [CrossRef] [PubMed]
  39. Nishimori, I.; Minakuchi, T.; Maresca, A.; Carta, F.; Scozzafava, A.; Supuran, C.T. The β-carbonic anhydrases from Mycobacterium tuberculosis as drug targets. Curr. Pharm. Des. 2010, 16, 3300–3309. [Google Scholar] [CrossRef]
  40. Güzel, O.; Maresca, A.; Scozzafava, A.; Salman, A.; Balaban, A.T.; Supuran, C.T. Discovery of low nanomolar and subnanomolar inhibitors of the mycobacterial beta-carbonic anhydrases Rv1284 and Rv3273. J. Med. Chem. 2009, 52, 4063–4067. [Google Scholar] [CrossRef]
  41. Nishimori, I.; Minakuchi, T.; Vullo, D.; Scozzafava, A.; Innocenti, A.; Supuran, C.T. Carbonic anhydrase inhibitors. Cloning, characterization, and inhibition studies of a new beta-carbonic anhydrase from Mycobacterium tuberculosis. J. Med. Chem. 2009, 52, 3116–3120. [Google Scholar] [CrossRef] [PubMed]
  42. Covarrubias, A.S.; Bergfors, T.; Jones, T.A.; Högbom, M. Structural mechanics of the pH-dependent activity of beta-carbonic anhydrase from Mycobacterium tuberculosis. J. Biol. Chem. 2006, 281, 4993–4999. [Google Scholar] [CrossRef] [PubMed]
  43. Suarez Covarrubias, A.; Larsson, A.M.; Högbom, M.; Lindberg, J.; Bergfors, T.; Björkelid, C.; Mowbray, S.L.; Unge, T.; Jones, T.A. Structure and function of carbonic anhydrases from Mycobacterium tuberculosis. J. Biol. Chem. 2005, 280, 18782–18789. [Google Scholar] [CrossRef] [PubMed]
  44. Khalifah, R.G. The carbon dioxide hydration activity of carbonic anhydrase: I. Stop-flow kinetic studies on the native human isoenzymes B and C. J. Biol. Chem. 1971, 246, 2561–2573. [Google Scholar] [CrossRef]
  45. Aksu, K.; Nar, M.; Tanc, M.; Vullo, D.; Gülçin, İ.; Göksu, S.; Tümer, F.; Supuran, C.T. Synthesis and carbonic anhydrase inhibitory properties of sulfamides structurally related to dopamine. Bioorg. Med. Chem. 2013, 21, 2925–2931. [Google Scholar] [CrossRef]
  46. Supuran, C.T. Carbonic anhydrase inhibition and the management of neuropathic pain. Expert Rev. Neurother. 2016, 16, 961–968. [Google Scholar] [CrossRef]
  47. McGurn, L.D.; Moazami-Goudarzi, M.; White, S.A.; Suwal, T.; Brar, B.; Tang, J.Q.; Espie, G.S.; Kimber, M.S. The structure, kinetics and interactions of the β-carboxysomal β-carbonic anhydrase, CcaA. Biochem. J. 2016, 473, 4559–4572. [Google Scholar] [CrossRef]
  48. Vermelho, A.B.; da Silva Cardoso, V.; Ricci Junior, E.; Dos Santos, E.P.; Supuran, C.T. Nanoemulsions of sulfonamide carbonic anhydrase inhibitors strongly inhibit the growth of Trypanosoma cruzi. J. Enzyme Inhib. Med. Chem. 2018, 33, 139–146. [Google Scholar] [CrossRef]
  49. Nocentini, A.; Carta, F.; Tanc, M.; Selleri, S.; Supuran, C.T.; Bazzicalupi, C.; Gratteri, P. Deciphering the mechanism of human carbonic anhydrases inhibition with sulfocoumarins: Computational and experimental studies. Eur. J. Chem. 2018, 24, 7840–7844. [Google Scholar] [CrossRef]
  50. Pustenko, A.; Nocentini, A.; Gratteri, P.; Bonardi, A.; Vozny, I.; Žalubovskis, R.; Supuran, C.T. The antibiotic furagin and its derivatives are isoform-selective human carbonic anhydrase inhibitors. J. Enzyme Inhib. Med. Chem. 2020, 35, 1011–1020. [Google Scholar] [CrossRef]
  51. Nocentini, A.; Bonardi, A.; Gratteri, P.; Cerra, B.; Gioiello, A.; Supuran, C.T. Steroids interfere with human carbonic anhydrase activity by using alternative binding mechanisms. J. Enzyme Inhib. Med. Chem. 2018, 33, 1453–1459. [Google Scholar] [CrossRef] [PubMed]
  52. Chohan, Z.H.; Munawar, A.; Supuran, C.T. Transition metal ion complexes of Schiff-bases. Synthesis, characterization and antibacterial properties. Met. Based Drugs 2001, 8, 137–143. [Google Scholar] [CrossRef] [PubMed]
  53. Ivanova, J.; Carta, F.; Vullo, D.; Leitans, J.; Kazaks, A.; Tars, K.; Žalubovskis, R.; Supuran, C.T. N-Substituted and ring opened saccharin derivatives selectively inhibit transmembrane, tumor-associated carbonic anhydrases IX and XII. Bioorg. Med. Chem. 2017, 25, 3583–3589. [Google Scholar] [CrossRef] [PubMed]
  54. Briganti, F.; Pierattelli, R.; Scozzafava, A.; Supuran, C.T. Carbonic anhydrase inhibitors. Part 37. Novel classes of isozyme I and II inhibitors and their mechanism of action. Kinetic and spectroscopic investigations on native and cobalt-substituted enzymes. Eur. J. Med. Chem. 1996, 31, 1001–1010. [Google Scholar] [CrossRef]
  55. Pastorekova, S.; Casini, A.; Scozzafava, A.; Vullo, D.; Pastorek, J.; Supuran, C.T. Carbonic anhydrase inhibitors: The first selective, membrane-impermeant inhibitors targeting the tumor-associated isozyme IX. Bioorg. Med. Chem. Lett. 2004, 14, 869–873. [Google Scholar] [CrossRef]
  56. Carta, F.; Supuran, C.T.; Scozzafava, A. Sulfonamides and their isosters as carbonic anhydrase inhibitors. Future Med. Chem. 2014, 6, 1149–1165. [Google Scholar] [CrossRef] [PubMed]
  57. Yıldırım, A.; Atmaca, U.; Keskin, A.; Topal, A.M.; Celik, M.; Gülçin, İ.; Supuran, C.T. N-Acylsulfonamides strongly inhibit human carbonic anhydrase isoenzymes I and II. Bioorg. Med. Chem. 2015, 23, 2598–2605. [Google Scholar] [CrossRef]
  58. Innocenti, A.; Gülçin, İ.; Scozzafava, A.; Supuran, C.T. Carbonic anhydrase inhibitors. Antioxidant polyphenols effectively inhibit mammalian isoforms I–XV. Bioorg. Med. Chem. Lett. 2010, 20, 5050–5053. [Google Scholar] [CrossRef]
  59. Schrödinger Suite Release 2022-4, Prime, v.5.5; Schrödinger, LLC: New York, NY, USA, 2022.
  60. Waterhouse, A.; Bertoni, M.; Bienert, S.; Studer, G.; Tauriello, G.; Gumienny, R.; Heer, F.T.; de Beer, T.A.P.; Rempfer, C.; Bordoli, L.; et al. SWISS-MODEL: Homology modelling of protein structures and complexes. Nucleic Acids Res. 2018, 46, W296–W303. [Google Scholar] [CrossRef]
  61. Srivastava, D.K.; Jude, K.M.; Banerjee, A.L.; Haldar, M.; Manokaran, S.; Kooren, J.; Mallik, S.; Christianson, D.W. Structural analysis of charge discrimination in the binding of inhibitors to human carbonic anhydrases I and II. J. Am. Chem. Soc. 2007, 129, 5528–5537. [Google Scholar] [CrossRef]
  62. Behnke, C.A.; Le Trong, I.; Godden, J.W.; Merritt, E.A.; Teller, D.C.; Bajorath, J.; Stenkamp, R.E. Atomic resolution studies of carbonic anhydrase II. Acta Crystallogr. D Biol. Crystallogr. 2010, 66, 616–627. [Google Scholar] [CrossRef]
  63. Buemi, M.R.; Di Fiore, A.; De Luca, L.; Angeli, A.; Mancuso, F.; Ferro, S.; Monti, S.M.; Buonanno, M.; Russo, E.; De Sarro, G.; et al. Exploring structural properties of potent human carbonic anhydrase inhibitors bearing a 4-(cycloalkylamino-1-carbonyl)benzenesulfonamide moiety. Eur. J. Med. Chem. 2019, 163, 443–452. [Google Scholar] [CrossRef] [PubMed]
  64. Berman, H.M.; Westbrook, J.; Feng, Z.; Gilliland, G.; Bhat, T.N.; Weissig, H.; Shindyalov, I.N.; Bourne, P.E. The Protein Data Bank. Nucleic Acids Res. 2000, 28, 235–242. [Google Scholar] [CrossRef]
  65. Schrödinger Suite Release 2022-4, Maestro v.13.2; Schrödinger, LLC.: New York, NY, USA, 2022.
  66. Schrödinger Suite Release 2022-4, Epik, v.6.0; Schrödinger, LLC.: New York, NY, USA, 2022.
  67. Schrödinger Suite Release 2022-4, Macromodel v.13.6.; Schrödinger, LLC.: New York, NY, USA, 2022.
  68. Schrödinger Suite Release 2022-4, Glide, v.9.5; Schrödinger, LLC.: New York, NY, USA, 2022.
  69. Schrödinger Suite Release 2022-4, Impact, v.9.5; Schrödinger, LLC.: New York, NY, USA, 2022.
  70. Lu, C.; Wu, C.; Ghoreishi, D.; Chen, W.; Wang, L.; Damm, W.; Ross, G.A.; Dahlgren, M.K.; Russell, E.; Von Bargen, C.D.; et al. OPLS4: Improving Force Field Accuracy on Challenging Regimes of Chemical Space. J. Chem. Theory Comput. 2021, 17, 4291–4300. [Google Scholar] [CrossRef] [PubMed]
  71. Kaminski, G.A.; Friesner, R.A.; Tirado-Rives, J.; Jorgensen, W.L. Evaluation and Reparametrization of the OPLS-AA Force Field for Proteins via Comparison with Accurate Quantum Chemical Calculations on Peptides. J. Phys. Chem. B 2001, 105, 6474–6487. [Google Scholar] [CrossRef]
  72. Bonardi, A.; Nocentini, A.; Cadoni, R.; Del Prete, S.; Dumy, P.; Capasso, C.; Gratteri, P.; Supuran, C.T.; Winum, J.Y. Benzoxaboroles: New Potent Inhibitors of the Carbonic Anhydrases of the Pathogenic Bacterium Vibrio cholerae. ACS Med. Chem. Lett. 2020, 11, 2277–2284. [Google Scholar] [CrossRef]
  73. Bonardi, A.; Nocentini, A.; Osman, S.M.; Alasmary, F.A.; Almutairi, T.M.; Abdullah, D.S.; Gratteri, P.; Supuran, C.T. Inhibition of α-, β- and γ-carbonic anhydrases from the pathogenic bacterium Vibrio cholerae with aromatic sulphonamides and clinically licenced drugs—A joint docking/molecular dynamics study. J. Enzyme Inhib. Med. Chem. 2021, 36, 469–479. [Google Scholar] [CrossRef] [PubMed]
  74. Grande, R.; Carradori, S.; Puca, V.; Vitale, I.; Angeli, A.; Nocentini, A.; Bonardi, A.; Gratteri, P.; Lanuti, P.; Bologna, G.; et al. Selective Inhibition of Helicobacter pylori Carbonic Anhydrases by Carvacrol and Thymol Could Impair Biofilm Production and the Release of Outer Membrane Vesicles. Int. J. Mol. Sci. 2021, 22, 11583. [Google Scholar] [CrossRef]
  75. Pettersen, E.F.; Goddard, T.D.; Huang, C.C.; Couch, G.S.; Greenblatt, D.M.; Meng, E.C.; Ferrin, T.E. UCSF Chimera—A visualization system for exploratory research and analysis. J. Comput. Chem. 2004, 25, 1605–1612. [Google Scholar] [CrossRef] [PubMed]
Molecules 28 04020 g001 550
Figure 1. (a) Selected examples of sulfonamide-containing carbonic anhydrase inhibitors (CAIs) in clinical use; (b) examples of sulfonamide–carbonyl thiourea hybrids reported in the literature as CAIs.
Figure 1. (a) Selected examples of sulfonamide-containing carbonic anhydrase inhibitors (CAIs) in clinical use; (b) examples of sulfonamide–carbonyl thiourea hybrids reported in the literature as CAIs.
Molecules 28 04020 g001
Molecules 28 04020 sch001 550
Scheme 1. General synthetic scheme of compounds 3a–3l.
Scheme 1. General synthetic scheme of compounds 3a–3l.
Molecules 28 04020 sch001
Molecules 28 04020 g002 550
Figure 2. Predicted binding mode of ligands 3d (green) and 3k (cyan) within the human (A) CA I; (B) CA II; (C) CA VII active sites. H-bonds, π-π stackings and π-cation interactions are represented as black, cyan and green dashed lines, respectively.
Figure 2. Predicted binding mode of ligands 3d (green) and 3k (cyan) within the human (A) CA I; (B) CA II; (C) CA VII active sites. H-bonds, π-π stackings and π-cation interactions are represented as black, cyan and green dashed lines, respectively.
Molecules 28 04020 g002
Molecules 28 04020 g003 550
Figure 3. Predicted binding mode of ligands 3d (green) and 3k (cyan) within the M. tuberculosis CA isoforms (A) MtCA1, (B) MtCA2 and (C) the MtCA3-HM active site. H-bonds and π-π stackings are represented as black and cyan dashed lines, respectively. The labels of amino acids from different chains are colored differently.
Figure 3. Predicted binding mode of ligands 3d (green) and 3k (cyan) within the M. tuberculosis CA isoforms (A) MtCA1, (B) MtCA2 and (C) the MtCA3-HM active site. H-bonds and π-π stackings are represented as black and cyan dashed lines, respectively. The labels of amino acids from different chains are colored differently.
Molecules 28 04020 g003
Table
Table 1. Inhibition constants (KI) of N-((4-sulfamoylphenyl)carbamothioyl) amides 3a–l against α-CAs (hCA I, II and VII) and β-CAs (mtCA1, mtCA2 and mtCA3) using AAZ as the standard with a stopped-flow CO2 hydrase assay [44].
Table 1. Inhibition constants (KI) of N-((4-sulfamoylphenyl)carbamothioyl) amides 3a–l against α-CAs (hCA I, II and VII) and β-CAs (mtCA1, mtCA2 and mtCA3) using AAZ as the standard with a stopped-flow CO2 hydrase assay [44].
CompoundKI (nM) a
hCA I
(α-CA)		hCA II
(α-CA)		hCA VII
(α-CA)		MtCA1
(β-CA)		MtCA2
(β-CA)		MtCA3
(β-CA)
3a85.278.713.5897.34.4610.2
3b58.335.92.8251.65.4806.0
3c50.37.73.0783.77.69396.5
3d87.4384.31.995.24.26284.1
3e72.78.91.1369.157.13670.6
3f36.45.32.1782.421.18393.7
3g13.346.53.235123.4718.7
3h67.821.72.26669.28.47144.4
3i60.59.72.6961.64.62125.9
3j69.464.610.324219.2850.7
3k47.99.23.1223.98.1446.6
3l87.66.82.5868.24.85275.4
AAZ25012.52.54809.8104
a Mean from 3 different assays using a stopped-flow technique (errors were in the range of ±5–10% of the reported values).
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Abdoli, M.; Bonardi, A.; Paoletti, N.; Aspatwar, A.; Parkkila, S.; Gratteri, P.; Supuran, C.T.; Žalubovskis, R. Inhibition Studies on Human and Mycobacterial Carbonic Anhydrases with N-((4-Sulfamoylphenyl)carbamothioyl) Amides. Molecules 2023, 28, 4020. https://doi.org/10.3390/molecules28104020

AMA Style

Abdoli M, Bonardi A, Paoletti N, Aspatwar A, Parkkila S, Gratteri P, Supuran CT, Žalubovskis R. Inhibition Studies on Human and Mycobacterial Carbonic Anhydrases with N-((4-Sulfamoylphenyl)carbamothioyl) Amides. Molecules. 2023; 28(10):4020. https://doi.org/10.3390/molecules28104020

Chicago/Turabian Style

Abdoli, Morteza, Alessandro Bonardi, Niccolò Paoletti, Ashok Aspatwar, Seppo Parkkila, Paola Gratteri, Claudiu T. Supuran, and Raivis Žalubovskis. 2023. "Inhibition Studies on Human and Mycobacterial Carbonic Anhydrases with N-((4-Sulfamoylphenyl)carbamothioyl) Amides" Molecules 28, no. 10: 4020. https://doi.org/10.3390/molecules28104020

APA Style

Abdoli, M., Bonardi, A., Paoletti, N., Aspatwar, A., Parkkila, S., Gratteri, P., Supuran, C. T., & Žalubovskis, R. (2023). Inhibition Studies on Human and Mycobacterial Carbonic Anhydrases with N-((4-Sulfamoylphenyl)carbamothioyl) Amides. Molecules, 28(10), 4020. https://doi.org/10.3390/molecules28104020

Article Metrics

Back to TopTop